Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Download Documentation 2016 Guidance Worksheet
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation Update on ABP-700
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation ABP-700 & MDCO-216 Conference Call Presentation
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.31 (0.77%)
Data as of 08/25/16 3:45 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
07/27/16The Medicines Company Reports Second-Quarter 2016 Business and Financial Results
— Advanced potential blockbuster R&D programs — — Completed divestiture of non-core cardiovascular assets — — Refinanced substantial portion of near-term debt obligations — — Transactions significantly strengthen balance sheet and provide valuable strategic and operational flexibility — PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 27, 2016-- The Medicines Company (NASDAQ:MDCO) today announced its business and financial resul... 
Printer Friendly Version
07/18/16The Medicines Company to Announce Second Quarter Financial Results on July 27, 2016
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 18, 2016-- The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for July 27, 2016 at 8:30 a.m. Eastern Time to discuss second quarter financial results and operational developments. The conference call will be available via phone and webcast. The dial-in information is listed below: Domestic Dial In: + 1 (877) 359-9508 International Dial In: + 1 (224) 357-23... 
Printer Friendly Version
07/12/16Federal Circuit Rules for The Medicines Company in Angiomax® (bivalirudin) Patent Litigation
The Federal Circuit unanimously affirms District Circuit decision on Angiomax patents PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 12, 2016-- The Medicines Company announced that the U.S. Court of Appeals for the Federal Circuit Court, in an en banc review, unanimously affirmed the earlier district court ruling in The Medicines Company v. Hospira, Inc., finding that the Company's Orange Book patents covering Angiomax® that expire in 2028 (pediatric... 
Printer Friendly Version
06/27/16The Medicines Company Announces Positive Top- Line Results for Phase 3 TANGO 1 Clinical Trial of CARBAVANCE®
CARBAVANCE (meropenem-vaborbactam) met both FDA and EMA pre-specified primary endpoints in patients with complicated urinary tract infections (cUTI) CARBAVANCE demonstrated statistical superiority over piperacillin-tazobactam, with overall success in 98.4% of treated patients, using FDA primary endpoint CARBAVANCE safety comparable to piperacillin-tazobactam TANGO 1 clinical data will s... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.